VTAMA
Total Payments
$21.3M
Transactions
149,968
Doctors
13,691
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $5.3M | 72,661 | 10,451 |
| 2023 | $14.0M | 71,882 | 10,137 |
| 2022 | $1.9M | 5,425 | 2,854 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $8.8M | 15,198 | 41.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6.3M | 2,486 | 29.8% |
| Food and Beverage | $2.9M | 129,001 | 13.7% |
| Consulting Fee | $2.3M | 545 | 10.8% |
| Travel and Lodging | $742,447 | 2,073 | 3.5% |
| Grant | $151,050 | 1 | 0.7% |
| Education | $12,561 | 664 | 0.1% |
Payments by Type
General
$12.5M
134,770 transactions
Research
$8.8M
15,198 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | Dermavant Sciences, Inc. | $4.9M | 0 |
| A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | Dermavant Sciences, Inc. | $2.7M | 0 |
| A Phase 4, open-label study to investigate the efficacy and safety of VTAMA(tapinarof) cream, 1% in the treatment of plaque psoriasis in intertriginous areas | Dermavant Sciences, Inc. | $536,093 | 0 |
| A Phase 4, open-label study to investigate the efficacy and safety of VTAMA(tapinarof) cream, 1% in the treatment of plaque psoriasis occurring in the head and neck region | Dermavant Sciences, Inc. | $332,244 | 0 |
| DMVT-505-3004 | Dermavant Sciences, Inc. | $174,880 | 0 |
| OPEN LABEL MAXIMAL USE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF TAPINAROF CREAM, 1% IN PEDIATRIC SUBJECTS WITH EXTENSIVE ATOPIC DERMATITIS | Dermavant Sciences, Inc. | $67,052 | 0 |
| A PHASE 4, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF VTAMA (TAPINAROF) CREAM, 1% IN THE TREATMENT OF PLAQUE PSORIASIS OCCURRING IN THE HEAD AND NECK REGION | Dermavant Sciences, Inc. | $57,765 | 0 |
| A PHASE 4, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF VTAMA (TAPINAROF) CREAM, 1% IN THE TREATMENT OF PLAQUE PSORIASIS IN INTERTRIGINOUS AREAS | Dermavant Sciences, Inc. | $14,300 | 0 |
Top Doctors Receiving Payments for VTAMA — Page 548
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Dermatology | Saint Louis, MO | $12.60 | 1 |
| , MD | Dermatology | Westerville, OH | $12.56 | 1 |
| , P.A.-C | Physician Assistant | Huntersville, NC | $12.53 | 1 |
| , MD | Dermatology | Mahwah, NJ | $12.50 | 1 |
| , PA | Physician Assistant | Temple, TX | $12.13 | 1 |
| , FNP-C | Family | Fort Payne, AL | $11.98 | 1 |
| , NP | Nurse Practitioner | Fort Payne, AL | $11.98 | 1 |
| , FNP-BC | Nurse Practitioner | Fort Payne, AL | $11.98 | 1 |
| , M.D | Dermatology | Fort Payne, AL | $11.98 | 1 |
| Dawn Barilli | — | Monroe, NY | $11.91 | 1 |
| Todd Brooks | Physician Assistant | Modesto, CA | $11.84 | 1 |
| , FNP-BC | Nurse Practitioner | Mishawaka, IN | $11.82 | 1 |
| , M.D | Dermatology | Vincennes, IN | $11.81 | 1 |
| Leo Conger | Dermatology | Belton, TX | $11.73 | 1 |
| , M.D | Dermatology | Yardley, PA | $11.72 | 1 |
| , FNP-C | Nurse Practitioner | Indianapolis, IN | $11.69 | 1 |
| , M.D | Specialist | Atlanta, GA | $11.67 | 1 |
Ad
Manufacturing Companies
- Dermavant Sciences, Inc. $21.3M
Product Information
- Type Drug
- Total Payments $21.3M
- Total Doctors 13,691
- Transactions 149,968
About VTAMA
VTAMA is a drug associated with $21.3M in payments to 13,691 healthcare providers, recorded across 149,968 transactions in the CMS Open Payments database. The primary manufacturer is Dermavant Sciences, Inc..
Payment data is available from 2022 to 2024. In 2024, $5.3M was paid across 72,661 transactions to 10,451 doctors.
The most common payment nature for VTAMA is "Unspecified" ($8.8M, 41.4% of total).
VTAMA is associated with 8 research studies, including "AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS" ($4.9M).